Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 287

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 287
---
-------|:--|:----|:---------------------------|:--|:----|:-----------------|---------:|
| Preferred SeriesC-1Agent Warrants |     |                      | 1,929 |     |                           | (1,929 | ) |     |                            | — |     |                  | 2,030.00 |
| Preferred SeriesC-2Agent Warrants |     |                      |   219 |     |                           | (219   | ) |     |                            | — |     |                  | 2,124.50 |
| Preferred SeriesC-3Agent Warrants |     |                      |   296 |     |                           | (296   | ) |     |                            | — |     |                  | 2,012.50 |
|                                   |     |                      | 2,444 |     |                           | (2,444 | ) |     |                            | — |     |                  |          |

9 Supplementary statement of cash flows information

The Company incurred the following non-cash investing and financing transactions (in thousands):

|                                                                                    |     | Three months endedSeptember 30, |       |     |       |     |
|                                                                                    |     |                           2024$ |       |     | 2023$ |     |
| Series C Preferred Stock common stock dividend (note 8)                            |     |                                 |    13 |     |       | 173 |
| Series A Preferred Stock cash dividend in accounts payable and accrued liabilities |     |                                 |     2 |     |       |   — |
| Conversion of Series C Preferred Stock to common stock (note 8)                    |     |                                 | 9,973 |     |       |  37 |
| Income taxes paid                                                                  |     |                                 |     — |     |       |   — |
| Interest paid                                                                      |     |                                 |     — |     |       |   — |

10 Financial instruments

The Company’s financial instruments are measured at fair value as determined by using the fair value hierarchy for inputs that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as